Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Peter Fasching, MD, from University Hospital Erlangen, Erlangen, Germany, comments on the importance of the development of therapies that can overcome resistance to hormone therapy, so that the use of chemotherapy for the treatment of breast cancer can be minimized.
